Juliana A Camargo1, Gabriela R Passos1, Karen L Ferrari1, Athanase Billis1, Mário J A Saad1, Leonardo O Reis2. 1. Faculty of Medical Sciences, University of Campinas, São Paulo, Brazil. 2. Faculty of Medical Sciences, University of Campinas, São Paulo, Brazil; Department of Urologic Oncology, Pontifical Catholic University of Campinas, São Paulo, Brazil. Electronic address: reisleo.l@gmail.com.
Abstract
BACKGROUND: The Toll-like receptor (TLR)2/4 agonist bacillus Calmette-Guérin (BCG), although not failure proof, has been the most efficient immunomodulatory treatment of immunogenic nonmuscle-invasive bladder cancer (NMIBC) for > 40 years. We investigated the role of the immunomodulatory molecule TLR7 agonist imiquimod through the BCG key receptors TLR2/4 and the main downstream molecules of the mammalian target of rapamycin pathway in NMIBC treatment. MATERIALS AND METHODS: A total of 40 Fischer-344 rats, 7 weeks old, received 4 doses of 1.5 mg/kg N-methyl-N-nitrosourea intravesically on weeks 0, 2, 4, and 6 for cancer induction. At week 8, the rats were randomized into 4 groups (10 per group) and treated intravesically once a week for 6 weeks: control (0.2 mL of vehicle); BCG (2 × 106 colony-forming units Connaught strain in 0.2 mL); imiquimod (20 mg/kg in 0.2 mL), and associated treatment BCG plus imiquimod in 0.2 mL. The bladders were extracted and analyzed for histopathology, immunohistochemistry, cell proliferation (Ki-67), apoptosis (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling [TUNEL]), and immunoblotting for TLR2, TLR4, p-P70S6K, and p-4E-BP1 proteins. RESULTS: The histopathology results showed that BCG and imiquimod decreased bladder tumorigenesis compared with the control group, with a proliferation decrease (Ki-67) and an apoptosis increase (TUNEL). BCG upregulated TLR2/4, imiquimod upregulated TLR4, and both downregulated P70S6K1. CONCLUSION: Imiquimod is able to efficiently decrease bladder carcinogenesis through upregulation of TLR7/4 and downregulation of P70S6K1 protein, generating new perspectives to boost BCG effects in the future.
BACKGROUND: The Toll-like receptor (TLR)2/4 agonist bacillus Calmette-Guérin (BCG), although not failure proof, has been the most efficient immunomodulatory treatment of immunogenic nonmuscle-invasive bladder cancer (NMIBC) for > 40 years. We investigated the role of the immunomodulatory molecule TLR7 agonist imiquimod through the BCG key receptors TLR2/4 and the main downstream molecules of the mammalian target of rapamycin pathway in NMIBC treatment. MATERIALS AND METHODS: A total of 40 Fischer-344 rats, 7 weeks old, received 4 doses of 1.5 mg/kg N-methyl-N-nitrosourea intravesically on weeks 0, 2, 4, and 6 for cancer induction. At week 8, the rats were randomized into 4 groups (10 per group) and treated intravesically once a week for 6 weeks: control (0.2 mL of vehicle); BCG (2 × 106 colony-forming units Connaught strain in 0.2 mL); imiquimod (20 mg/kg in 0.2 mL), and associated treatment BCG plus imiquimod in 0.2 mL. The bladders were extracted and analyzed for histopathology, immunohistochemistry, cell proliferation (Ki-67), apoptosis (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling [TUNEL]), and immunoblotting for TLR2, TLR4, p-P70S6K, and p-4E-BP1 proteins. RESULTS: The histopathology results showed that BCG and imiquimod decreased bladder tumorigenesis compared with the control group, with a proliferation decrease (Ki-67) and an apoptosis increase (TUNEL). BCG upregulated TLR2/4, imiquimod upregulated TLR4, and both downregulated P70S6K1. CONCLUSION: Imiquimod is able to efficiently decrease bladder carcinogenesis through upregulation of TLR7/4 and downregulation of P70S6K1 protein, generating new perspectives to boost BCG effects in the future.
Authors: Katherine A Michaelis; Mason A Norgard; Peter R Levasseur; Brennan Olson; Kevin G Burfeind; Abigail C Buenafe; Xinxia Zhu; Sophia Jeng; Shannon K McWeeney; Daniel L Marks Journal: Brain Behav Immun Date: 2019-09-06 Impact factor: 7.217
Authors: Isis G A Kiehl; Eduardo Riccetto; Ana C C Salustiano; Marina V Ossick; Karen L Ferrari; Heloisa B Assalin; Osamu Ikari; Leonardo O Reis Journal: World J Urol Date: 2020-06-02 Impact factor: 4.226
Authors: Katherine A Michaelis; Mason A Norgard; Xinxia Zhu; Peter R Levasseur; Shamilene Sivagnanam; Shannon M Liudahl; Kevin G Burfeind; Brennan Olson; Katherine R Pelz; Diana M Angeles Ramos; H Carlo Maurer; Kenneth P Olive; Lisa M Coussens; Terry K Morgan; Daniel L Marks Journal: Nat Commun Date: 2019-10-15 Impact factor: 14.919
Authors: Alessandro Audisio; Consuelo Buttigliero; Marco Donatello Delcuratolo; Elena Parlagreco; Marco Audisio; Antonio Ungaro; Rosario Francesco Di Stefano; Lavinia Di Prima; Fabio Turco; Marcello Tucci Journal: Cells Date: 2022-01-21 Impact factor: 6.600